Italy's Amplifon FY 2025 revenue rises 1.7%

Amplifon SpA

04/03/2026 16:56

Overview

Hearing solutions provider's FY 2025 revenue grew 1.7% yr/yr at constant exchange rates to 2.4 bln euros

Adjusted EBITDA for FY 2025 was 540.4 mln euros, margin at 22.6%

Company highlights Fit4Growth program's contribution to improved performance

Outlook

Company expects solid improvement in organic growth for 2026

Amplifon anticipates adjusted EBITDA margin in high end of +150-200 bps range by 2027

Company plans divestiture of UK business

Result Drivers

FIT4GROWTH PROGRAM - Amplifon attributed improved adjusted EBITDA margin to Fit4Growth program

ORGANIC GROWTH - Significant improvement in organic growth in the second half contributed to revenue increase

GEOGRAPHIC EXPANSION - Acquisitions in France, Germany, and Poland contributed to revenue growth

Company press release: ID:nBIA7xsvPX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
EUR 2.4 bln
FY Capex
EUR 116.7 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 11 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Amplifon SpA is €17.00, about 37.2% above its March 3 closing price of €12.39

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 17 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)